113 related articles for article (PubMed ID: 17237473)
1. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Chau I; Cunningham D; Hickish T; Massey A; Higgins L; Osborne R; Botwood N; Swaisland A
Ann Oncol; 2007 Apr; 18(4):730-7. PubMed ID: 17237473
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Hartmann JT; Pintoffl JP; Kröning H; Bokemeyer C; Holtmann M; Höhler T
Onkologie; 2008 May; 31(5):237-41. PubMed ID: 18497512
[TBL] [Abstract][Full Text] [Related]
3. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Horiike A; Kudo K; Miyauchi E; Ohyanagi F; Kasahara K; Horai T; Nishio M
Br J Cancer; 2011 Oct; 105(8):1131-6. PubMed ID: 21915126
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Aparicio J; de las Peñas R; Vicent JM; Garcerá S; Llorca C; Maestu I; Yuste AL; Farrés J
Oncology; 2002; 63(1):42-7. PubMed ID: 12187070
[TBL] [Abstract][Full Text] [Related]
9. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Chau I; Norman AR; Cunningham D; Waters JS; Topham C; Middleton G; Hill M; Ross PJ; Katopodis R; Stewart G; Oates JR
Br J Cancer; 2004 Oct; 91(8):1453-8. PubMed ID: 15365570
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Veronese ML; Sun W; Giantonio B; Berlin J; Shults J; Davis L; Haller DG; O'Dwyer PJ
Br J Cancer; 2005 May; 92(10):1846-9. PubMed ID: 15870719
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan RC; Furman W; Mao S; Wu J; Turner DC; Stewart CF; Santana V; McGregor LM
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1191-8. PubMed ID: 25257509
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
Carnaghi C; Rimassa L; Garassino I; Zucali PA; Masci G; Fallini M; Morenghi E; Santoro A
Ann Oncol; 2002 Sep; 13(9):1424-9. PubMed ID: 12196368
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Middleton G; Brown S; Lowe C; Maughan T; Gwyther S; Oliver A; Richman S; Blake D; Napp V; Marshall H; Wadsley J; Maisey N; Chau I; Hill M; Gollins S; Myint S; Slater S; Wagstaff J; Bridgewater J; Seymour M
Eur J Cancer; 2013 Nov; 49(16):3507-16. PubMed ID: 23953030
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L
Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
